Eventide Asset Management’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
Other funds holding PTGX
Eventide Asset Management's PTGX Position: Q3 2026 in Review
Eventide Asset Management increased its Protagonist Therapeutics (PTGX) stake by 18% in Q3 2026, buying an estimated $83.1K and bringing the position to 3,870 shares worth $546K. The position accounts for 0.01% of the portfolio, ranked #246.
Eventide Asset Management first reported a position in PTGX in Q2 2017 and has held it in 8 quarters since. The position peaked at $8.84M in Q2 2023. 328 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.
- Eventide Asset Management held 3,870 shares of Protagonist Therapeutics worth $546K as of Q3 2026.
- Eventide Asset Management bought 583 Protagonist Therapeutics shares in Q3 2026, an estimated $83.1K.
- Protagonist Therapeutics made up 0.01% of Eventide Asset Management's portfolio in Q3 2026, its #246 holding.
- Eventide Asset Management first reported a position in Protagonist Therapeutics in Q2 2017 and has held it in 8 quarters since.
- Eventide Asset Management's Protagonist Therapeutics position peaked at $8.84M in Q2 2023.
- 328 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.
Based on Eventide Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.